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Abstract
Despite recent major clinical breakthroughs in human cancer immunotherapy including the use of checkpoint
inhibitors and engineered T cells, important challenges remain, including determining the sub-populations of
patients who will respond and who will experience at times significant toxicities. Although advances in cancer
immunotherapy depend on preclinical testing, the majority of in-vivo testing currently relies on genetically identical
inbred mouse models which, while offering critical insights regarding efficacy and mechanism of action, also vastly
underrepresent the heterogeneity and complex interplay of human immune cells and cancers. Additionally,
laboratory mice uncommonly develop spontaneous tumors, are housed under specific-pathogen free conditions
which markedly impacts immune development, and incompletely model key aspects of the tumor/immune
microenvironment. The canine model represents a powerful tool in cancer immunotherapy research as an
important link between murine models and human clinical studies. Dogs represent an attractive outbred
combination of companion animals that experience spontaneous cancer development in the setting of an intact
immune system. This allows for study of complex immune interactions during the course of treatment while also
directly addressing long-term efficacy and toxicity of cancer immunotherapies. However, immune dissection
requires access to robust and validated immune assays and reagents as well as appropriate numbers for statistical
evaluation. Canine studies will need further optimization of these important mechanistic tools for this model to
fulfill its promise as a model for immunotherapy. This review aims to discuss the canine model in the context of
existing preclinical cancer immunotherapy models to evaluate both its advantages and limitations, as well as
highlighting its growth as a powerful tool in the burgeoning field of both human and veterinary immunotherapy.
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Background
The ability of the immune system to recognize and eradi-
cate transformed cells is the central rationale behind the
application of immunotherapy for cancer [1]. Recent
breakthrough developments in cancer immunotherapy
include checkpoint blockade therapy targeting cytotoxic
T-lymphocyte-associated antigen 4 (CTLA-4) and pro-
grammed death receptor-1 (PD-1) as well as adoptive
transfer of engineered T cells or chimeric antigen receptor
(CAR) T cells [2–9]. Yet, despite the exciting success of
these therapies, only a fraction of patients durably re-
sponds to treatment. Hence, a critical issue for the clinical
translation of cancer immunotherapy is determining fac-
tors predictive of response, and unlike traditional chemo-
therapy or targeted therapy, key aspects of the patient’s
immune milieu are likely to be as important as tumor-
related factors in determining response and toxicity.
Data from experiments in mouse models have been
invaluable to understand mechanistic concepts of immuno-
therapy. However, intrinsic characteristics of mouse models
create challenges for clinical translation. In particular, pre-
clinical models with intact immune systems that closely
mimic the human immune system, display comparable,
spontaneous oncogenesis and immune interactions to
* Correspondence: wculp@ucdavis.edu; wmjmurphy@ucdavis.edu
†Equal contributors
4The Center for Companion Animal Health, Department of Surgical and
Radiological Sciences, School of Veterinary Medicine, University of
California-Davis, Davis, CA95616USA
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Park et al. Journal for ImmunoTherapy of Cancer  (2016) 4:97 
DOI 10.1186/s40425-016-0200-7
humans, and that can model key immunotherapeutic
outcomes such as efficacy, dose response, and toxicity,
will be critical for progress in translational cancer im-
munotherapy research.
In this review, we will highlight why the study of spon-
taneous cancers in companion animal dogs is an attractive
model for overcoming obstacles in cancer immunotherapy
research. First, cancer is a leading cause of death in dogs,
as it is for humans. Consequently, the use of companion
dogs for the study of cancer biology and treatment has
been advocated by veterinarians and other translational
researchers for more than 50 years [10–16] Secondly, dogs
are large, outbred animals that develop cancer spontan-
eously. The parallel evolutionary history of humans and
dogs also has led to greater similarities in the organization
of the canine and the human genomes than what is
observed between humans and mice, as well as shared
exposure to environmental risk factors. Together, these
traits appear to make dogs a very attractive translational
model for cancer immunotherapy.
Preclinical models as tools for cancer immunotherapy
For over 100 years, preclinical animal models have been
the foundation for the development of novel cancer
therapies. Historically, this foundation has relied on
mouse models, and there is no question that these
models remain fundamentally important today [17, 18].
The vast majority of current in vivo cancer biology stud-
ies use inbred laboratory mice, and the pre-eminence of
rodent studies in cancer experimental therapeutics is
unlikely to be displaced in the near future. In particular,
genetically engineered mice (GEM) have been especially
informative regarding mechanisms of oncogenesis and
the identification of novel targets for therapy. However,
practical considerations limit the number of genes and
mutations that can be effectively studied in GEM
models. Furthermore, GEM tumors also might under-
represent the heterogeneity and complexity of spontan-
eous human malignancies, potentially oversimplifying
cancer immunotherapy studies where tumor-host inter-
actions, immuno-editing, and immune evasion are key
issues [17, 19].
Laboratory mice are generally genetically homogenous,
matched for size, age and sex, fed identical diets and
housed in specific pathogen-free (SPF) environments.
All of these factors are critical for carefully controlled
and executed mechanistic studies of promising new anti-
cancer agents, but there are increasingly recognized
limitations of mouse models. For example, a somewhat
controversial study by Seok et al. simultaneously ana-
lyzed the genetic changes occurring in humans and mice
following inflammatory insults such as burns, trauma
and endotoxemia. Although there was high genomic
similarity after different inflammatory conditions among
different human subjects, a surprisingly poor correlation
of genomic changes was observed between humans and
mice [20]. Consequently, although there have been sub-
sequent reports challenging these findings, this study
was an important statement on the limitations of mouse
models for the study of human disease and underscored
the potential for differences in mouse and human biol-
ogy to confound results. Moreover, it is increasingly
recognized that studies using young, sex-matched, typic-
ally female mice often fail to accurately represent the
older, obese and heterogeneous human population that
develops cancer [17, 21]. These are important consider-
ations given that only 11% of oncology drugs which
work in mice are ever approved for human use [22, 23].
There are other aspects of the controlled environment
in which inbred mice are housed that can create an in-
accurate representation of the human disease. For
example, differences of environmental/microbiome fac-
tors have recently been implicated in response to cancer
treatments, including immunotherapy. In fact, recent
studies demonstrated that differences in the gut micro-
biota of mice raised in SPF environments at different
research institutions affect both tumor growth rates and
responses to immunotherapy [24–26]. In contrast to
mice, pet dogs seem to share many features of the hu-
man microbiome. Song et al. analyzed the effects of co-
habitation among related and non-related children and
adults as well as dogs living in the same household on
the range of microorganisms found on the skin and the
intestines. The authors observed that co-habitation, in-
cluding dog-human co-habitation, likely from frequent
contact, was the strongest predictor of similarities in
microbiota with the skin showing the highest concordance
[27]. Microbiome studies in dogs have also demonstrated
that the resident microbiota is an important driver of host
immunity and inflammation [28]. Although detailed stud-
ies of the microbiome in dogs undergoing cancer treat-
ment or immunotherapy have not been performed, the
studies to date highlight the potential for dog microbiome
studies to be generalizable to and representative of the
broader human population.
A greater challenge for translational immunotherapy is
that many laboratory models now utilize immunocom-
promised mice as hosts for human tumor-immune cell
xenografts and patient-derived xenografts (PDX). As the
constituent elements of the immune system are not
completely represented in these animals, the models fail
to represent the full complexity of tumor-host interac-
tions. Humanized mice that recapitulate components of
the human hematopoietic and immune system circum-
vent some of the concerns associated with studies using
immunodeficient mice and therefore represent potential
translational tools [23, 29]. However, these models are
costly, technically complicated (MHC-typing or use of
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transgenic mice are necessitated), and ultimately still
lack critical functional components of the human im-
mune system, which limits their ability to truly mimic
the context in which spontaneous human cancers
develop [19].
Moreover, despite the increasing sophistication of hu-
manized mouse models (of which HLA- and human
cytokine transgenic mice are available) as well as other
key advances in mouse cancer modeling, pre-clinical
mouse models are still limited by artificial factors such
as the SPF environment in which inbred mice are
housed, leading to unrepresentative environmental/mi-
cro-environmental factors, including the microbiome.
Chronic viral infections (such as Epstein-Barr virus and
cytomegalovirus) that heavily shape the human immune
system repertoire are also not present. Recent studies
have demonstrated that mice raised in SPF environ-
ments in different institutions will manifest distinct
microbiota which affects rates of tumor growth and im-
munotherapy responses, raising key questions about
host-tumor interactions in the response to immunother-
apy [24–26].
Of all animal models, non-human primates (NHP) are
the most similar to humans in their genetic composition
[30]. Yet, interestingly, but for unclear reasons, NHP
raised in conventional primate centers have a low inci-
dence of spontaneous cancer (while cancer incidence
and prevalence for NHP in the wild is unknown) [31].
As a result, NHP have proven less useful as tumor
models. Furthermore, the high cost of breeding and
housing NHP as well as ethical issues are important bar-
riers to their use as a preclinical model [32].
The limitations of conventional mouse models under-
score the need for novel approaches to understand the
spectrum of responses, both in terms of efficacy and tox-
icity, which are observed in human cancer patients that
receive immunologic and biological therapies. We
propose that the dog model provides a critical link in
pre-clinical studies since dogs are large, outbred, im-
munocompetent animals that develop spontaneous tu-
mors. The principal advantages and disadvantages of the
various pre-clinical animal models for cancer immuno-
therapy studies are summarized in Table 1.
Canine cancers
Although rigorous epidemiological data are not available
for companion animals, current estimates suggest that
approximately 2–4,000,000 dogs in the US are diagnosed
with cancer annually [33, 34]. Overall, the best available
data estimate that approximately one in four dogs in the
US will be diagnosed with cancer, which (if confirmed)
would translate to an incidence of canine cancers per
year strikingly greater (5300 cases/ 100,000 dogs) than
that of humans (500 cases/ 100,000 persons) [33, 34].
With growing cancer diagnoses in both human and
canine populations, spontaneous cancers in dogs make
Table 1 Summary of Commonly Used Immunotherapy Models/Systems
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them ideal for the study of cancer biology and immuno-
therapy, especially since pet owners are highly driven to
seek out novel treatments for their companion animals.
Moreover, with the decoding of the canine genome,
important similarities between dog and human oncogen-
esis, including specific cancer-associated genes such as
BRAFV600E, p53, Bcr-Abl, and c-kit have been recognized
[35–37]. In osteosarcoma (OSA), for example, gene ex-
pression profiling has demonstrated remarkable homology
between canine and human forms of the disease, reinfor-
cing the shared biology between dog and human [38, 39].
In addition, cancers that develop in dogs show the
same complex interplay of genetics, age, and environ-
mental exposures as in humans [12, 33, 40, 41], and
these similarities are stronger between humans and dogs
than they are between humans and mice [30, 33, 42–44].
As with humans, cancer incidence in dogs is associated
with increasing age, although certain cancers do display
distinct epidemiological patterns between dogs and
people [45, 46]. For example, in humans, OSA is mark-
edly more common in children and adolescents, whereas
the diagnosis peaks in middle age to older dogs between
7 and 9 years [47]. Interestingly, the risk of OSA in dogs
also increases with increasing body weight and is specif-
ically associated with large and giant breeds such as
Great Danes, Saint Bernards and Irish wolfhounds [48].
Somewhat paradoxically, although outbred at the species
level, the genetic diversity of dogs is also quite restricted
at the breed level [44]. This artificial genetic selection
has clearly placed different breeds at elevated risk for
certain malignancies as shown in Table 2 [34, 49].
Although dogs develop cancers from tissues throughout
the body similar to humans, the incidence and prevalence
of different tumor types show other notable differences
from human counterparts. For example, while OSA, ma-
lignant mast cell tumors, and hemangiosarcoma are some
of the most common malignancies in dogs, these cancers
are uncommon in humans [34, 47]. Similarly, while non-
Hodgkin’s lymphoma (NHL) occurs in humans with an
estimated incidence rate of 19.6 per 100,000 people, NHL
occurs with an even greater frequency in dogs (in 2014,
approximately 250,000 cases of lymphoma were diagnosed
in dogs versus approximately 71,000 cases in humans)
[50–54]. Conversely, human colorectal, pancreatic and
pulmonary carcinomas that cumulatively account for
approximately 40% of estimated cancer deaths in the US,
are much less common in dogs with an incidence of less
than 1% for each tumor type [55]. Furthermore, there is a
markedly lower incidence of canine breast cancer in the
US than in other parts of the world or in humans, almost
certainly due to the routine practice of spaying dogs in the
US [56–59]. Nevertheless, it is important to recognize
these differences in the incidence and prevalence of
specific cancer types between humans and dogs because
these differences impact the translational relevance of ca-
nine cancer studies to humans. However, such variations
can also be advantageous for clinical translation of novel
cancer therapies since the higher incidence of OSA and
hemangiosarcoma in canines, for example, can be utilized
to obtain clinical data more rapidly than what is achiev-
able in humans with these rare tumors.
Prior to the recent growth in companion animal clin-
ical trials, the laboratory research beagle represented a
more standardized way to proceed with experiments in
canines. International requirements, particularly in the
United Kingdom and in Europe, require toxicology and
Table 2 Common Canine Cancers with Key Demographic Features
Cancer Incidence Age of Onset (years) Location Breeds at Elevated Riska
Gliomas 2–3X more common in
dogs than people
Variable, majority > 6 Intracranial Boxers, bulldogs, and terriers
Lymphoma ~250,000 new cases per
year (2/3 B cell lymphoma)
7–10 Multicentric/external
lymph nodes
Golden Retriever, Boxers, Bullmastiffs,
Basset Hounds, Saint Bernards, Scottish
Terriers, Airedales, Bulldogs
Mammary Carcinoma Uncommon in spayed female
dogs, 10–15% of unspayed
females
10–11 Breast tissue Poodles, Dachshunds, and Spaniels
Melanoma 5–10% of dog cancer deaths ≥10 Mouth, toenail bed,
and skin
Terriers, Retrievers, Schnauzers, and
Chow Chows
Osteosarcoma 50,000–75,000 cases per
year (~75X more common
in dogs)
Bimodal, highest
peak at age 7–10
Axial and appendicular
skeleton
Labradors, Golden Retrievers, German
Shepherds, Dobermans, Weimeraners,






~10X more common in
dogs than humans
All ages Soft tissues Labrador Retriever, Golden Retriever,
German Shepherd, Bernese Mountain
Dog
aData on breed predisposition of specific cancers are potentially subject to reporting bias given differences in breed popularity and differences in how owners
may seek veterinary care
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pharmacology studies in at least two animal species, a
rodent and non-rodent, prior to human clinical trials.
The non-rodent model is frequently the research beagle,
which has been chosen because of its relatively small
size as well as its passive nature and affable personality.
A single breed also minimizes breed variability that
might otherwise exist among studies. Choi et al. and
Ikeuchi et al. have provided reference values for
hematological, serum biochemical and urological, as well
as organ weight parameters to establish a standardized
set of normal values, and minimize the use of laboratory
canines for baseline studies [60, 61]. However, breed-
related variations in hematologic and serum biochemical
values have been reported, signaling caution in applying
immunologic findings from beagle studies to other dog
breeds [62, 63]. Curiously, laboratory beagles anecdotally
appear to be less sensitivity to toxicity than most pet
dogs [64]. In fact, it has been recommended that when
undertaking a Phase I clinical trial of a chemotherapy
agent in client-owned dogs, the first dose administered
should be 50% of the maximum tolerated dose observed
in laboratory beagles because of their apparent favorable
toxicity profile. Although the reason for this remains un-
known, it does reinforce the concept that data derived
from laboratory beagles may not be easily compared to
that obtained from client-owned dogs and other breeds.
Canine clinical oncology
As in humans, cancer treatment of pet dogs relies prin-
cipally on surgery, chemotherapy and radiation therapy
(RT), with several nuances. The decision for dog owners
to pursue cancer treatment for their pets may be driven
by several considerations including the desire to improve
their pet’s quality of life, especially if a cure is not likely,
and to prevent or delay recurrence or metastasis. Argu-
ably, the implicit goal of cancer treatment in companion
dogs is to elicit maximum benefit while preserving opti-
mal quality of life. Thus, lower doses of chemotherapy
agents are frequently delivered to dogs than would be to
humans in order to avoid severe toxicity. Another impli-
cit assumption is that cancer care in dogs is more likely
to be palliative in intent, rather than curative. Although
conventional therapies are typically offered, and ‘stand-
ard of care’ approaches are recommended, owners fre-
quently elect experimental therapies for their dogs
(including participation in clinical trials) when there is
no current ‘standard of care’ for that tumor type, or for
altruistic reasons, or due to financial limitations. In vet-
erinary medicine, financial incentives to participate in
clinical trials are not considered to be unethical or coer-
cive, since those clinical trials frequently include ‘stand-
ard of care’ human cancer therapies as the backbone of
therapy in addition to an investigational agent [65].
In addition, there is no established “standard-of-care”
for certain types of dog cancer, so these patients are
treated using a variety of different approaches based on
published literature and clinician preference, and in
some cases owners are reluctant to subject their pet dog
to potentially morbid procedures such as surgery and
RT. Chemotherapy is recommended in the adjuvant set-
ting for highly metastatic tumors such as OSA, or as
first-line therapy for systemic cancers such as lymphoma,
multiple myeloma, and others. Multi-agent chemotherapy
is the recommended treatment for high-grade lymphomas
(most commonly diffuse large B-cell lymphoma) in the
dog [66]. In addition, since the chimeric mAb rituximab
binds an epitope of human CD20 that is not conserved in
dogs, numerous canine specific anti-CD20 mAbs are in
various stages of development for the study and treatment
of dog lymphoid neoplasms [66–70].
As in humans, assessment of response to cancer ther-
apy, especially in the metastatic setting, frequently relies
on serial imaging studies. Although the recommended
imaging modality will depend on the tumor type and
location, in dogs it typically includes thoracic radio-
graphs and/or abdominal ultrasound. While computed
tomography (CT) and magnetic resonance imaging are
readily available and routinely used in clinical veterinary
medicine and positron emission tomography is becom-
ing more accessible, they require general anesthesia in
dogs and cost significantly more than these other modal-
ities [71]. Another important aspect of veterinary medi-
cine, particularly for comparative researchers evaluating
novel cancer therapies in dogs, is that death in client-
owned animals is frequently the result of euthanasia. As
such, it is important to recognize the potential for this to
bias the results, especially in unblinded and non-
randomized studies evaluating survival as the endpoint.
Of note, many owners are willing to let their dog undergo
a necropsy examination after death or euthanasia. Al-
though this allows for more detailed assessment of tumor
responses, immune cell infiltration and potential treat-
ment toxicities, as in humans, successful utilization can be
variable and unpredictable.
Canine immune assays
Although there are many advantages to the canine
model, currently a key barrier to detailed mechanistic/
correlative studies (outside of the inherent variability
and cost associated with clinical monitoring in large
numbers) in canine models and clinical trials is the
paucity of widely available, standardized, and validated
canine reagents for laboratory use. For example, al-
though the fundamental components of the dog immune
system have been examined to date, characterization of
specific components has been much less detailed. Neo-
natal and post-natal studies of dogs suggest that canines
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resemble humans and differ from rodents in that dogs
appear to be immunologically competent at, or before,
birth [72]. Moreover, similar to humans, the phenotype of
lymphocytes in the peripheral blood and tumor micro-
environment of dogs with cancer has been linked with
prognosis. For example, Estrela-Lima et al. observed that
both increased tumor-infiltrating lymphocytes based on
phenotypic analysis of single cell suspension of tumor
tissue by flow cytometry and increased blood CD4/CD8
ratios were correlated with worse survival in canine mam-
mary cancers [73]. Similarly, elevated Tregs, tumor-
associated macrophages, and myeloid-derived suppressor
cells, respectively, have been associated with adverse out-
come in canine B cell lymphoma and mammary tumors
[74–76]. Although these studies reinforce the impression
of important homology between dog and human immu-
nobiology, especially in cancer, they also highlight the
correlative nature of many canine studies with a notable
absence of carefully controlled and functional experiments
to satisfy high levels of evidence regarding causation and
mechanism. Interestingly, there is evidence for breed ef-
fects on immune function which likely relate to the inher-
itance of particular haplotypes of major histocompatibility
complex (MHC) genes and further reinforce the paradox
that dogs are a highly outbred species which nevertheless
manifest significant effects of genetic inbreeding [77–79].
To address the increasing focus on canine models,
researchers and vendors have recently focused on the
development and dissemination of commercially avail-
able, canine-specific antibodies for basic and transla-
tional research, as researchers often rely on human and
mouse antibodies which have been validated to be cross-
reactive for canine markers. Table 3 shows some cell
surface markers that are used to phenotype the various
canine immune subsets. Mixed-lymphocyte reactions,
co-culture killing assays (Chromium release and/or flow
cytometry based), IFN ELISPOT, intracellular cytokine
staining, and phagocytic activity of dendritic cells using
fluorescent-labeled latex beads are all standard immune
functional assays used in canine models [80].
Characterization of canine immunoglobulins dates to
the work of Johnson et al. in 1967 [16]. While this body
of work, and studies that followed, demonstrated that
canine IgGs consist of four subclasses, the diverse func-
tions and interactions of canine immunoglobulins with
other immune effector cells have remained less charac-
terized [81]. Nevertheless, there has been a longstanding
interest in canine specific mAbs, including canine-CD20
targeted antibodies, for therapeutic and diagnostic use
[66, 68, 69]. Important for cross-species translational
studies, Bergeron et al. demonstrated that canine Fc
gamma receptors bind to dog, human, and mouse IgGs,
suggesting that a human therapeutic antibody could be
effective at stimulating ADCC in a canine therapeutic
model, although species differences may result in signifi-
cant differences in activity as well as eventual
neutralization by the host [81]. Speciated antibodies in a
dog IgG framework are now routinely developed using
the hypervariable regions of the variable antigen-binding
domain (Fv) derived from mouse antibodies [81]. Im-
portant for immunotherapy studies, expression of check-
point molecules, including PD-L1, has been observed on
several canine tumors including mastocytoma, melan-
oma, and renal cell carcinoma [82], and elevated CTLA-
4 expression using mouse anti-human antibodies has
been observed in dog histiocytic sarcoma patients com-
pared to healthy controls [83]. Unfortunately, studies to
explore immune checkpoint blockade in dogs will have
to wait as reagents against canine PD1, PDL-1, and
CTLA-4 are not yet commercially available, nor do they
exist in formats that are suitable for clinical translation.
Overall, the major immune subsets have been character-
ized in dogs, and significant homology with humans has
been demonstrated, but notable differences have also been
observed. In 1994, an international Canine Leukocyte
Antigen Workshop was held, establishing important ca-
nine homologues for key leukocyte populations such as
CD4, CD8, and CD90 [84]. Subsequently, homologues of
CD45R, CD45RA, CD11, and CD62L were also identified.
However, despite these advances, characterizing naïve,
Table 3 Phenotype of Canine Immune Subsets
Cell Positive CD Markers Negative CD Markers
Helper T cell CD4,a CD45 CD21
Cytotoxic T cell CD8, CD45, IFN-γ CD21
Activated Memory T cell CD25, CD44, CD45, CD69 CD62L
Regulatory T cell CD4, CD25, CD45, FoxP3 CD8
B cell CD22, CD79a, CD45, CD25, MHC2 TCR
Dendritic cell CD11c, MHC II, CD80, CD14 N/A
Macrophage MHC II, Mac-3/Lamp2/107b, F4/80, CD11b, CD206 N/A
Natural Killer cell CD5 dim, CD45, MHC1, MHC2, NKp46 CD5 (after 14 days in culture), CD4, CD21
aPossibly unique to canines, CD4 is expressed in granulocytes. Similar to other species, CD4 is expressed in a subset of monocyte-derived cells
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activated, and memory subsets for T cells and other im-
mune effector cells has remained limited. For example,
Isotani et al. characterized canine dendritic cells with
morphology and phagocytic function comparable to
mouse and human DCs [80]. In addition, the DCs demon-
strated expression of MHC class II, CD11c, CD80, and
CD86, and these markers have been used to identify ca-
nine DCs in other studies [80]. In another important
study, Hartley et al. used multiple cross-reactive anti-
bodies including rat anti-human CCR7 and mouse anti-
human CD62L to show downregulation of these surface
molecules on activated T cells. Based on these data, the
authors proposed a schema for distinguishing canine
central memory T cells (CCR7+CD62LhiCTL2.58−) from
activated T cells (CCR7−CD62LloCTL2.58+) [85].
Conversely, dog NK cells have proved more difficult to
characterize as dogs do not express CD56 and marker
systems such as CD3-CD5dim have been used to describe
NK cell activity. Overall, although a clear consensus has
not yet emerged [86–88], recent work of Foltz et al. and
Grondahl-Rosado et al. have independently demon-
strated that canine NKp46 expression appears to identify
a canine CD3− lymphocyte population with characteris-
tics and cytotoxicity of NK cells [89–91].
Canine immunotherapy and clinical trial design
The growing application of cancer immunotherapy to
veterinary medicine has been discussed in detail by
recent comprehensive reviews [92, 93]. Although a fre-
quent approach is to apply novel human anti-cancer
agents including immunotherapy to veterinary patients,
it is also increasingly common to see novel agents intro-
duced in companion animals first. Oncept® is an example
of a xenogeneic cDNA vaccine which contains a plasmid
expressing the human tyrosinase enzyme. It is USDA-
approved for the treatment of stage II or III canine
oral melanoma. (In veterinary medicine, DNA vac-
cines and live vaccines are approved by the USDA ra-
ther than the FDA - http://www.fsis.usda.gov/wps/portal/
fsis/topics/regulations/directives/7000-series/mou-fsis-fda).
Although the ultimate effectiveness of Oncept® is contro-
versial, the heterogeneity of responses observed with this
treatment illustrates an important aspect of dog immuno-
therapy studies which is both a strength and a weakness of
the dog model, namely that responses are variable and
multifactorial in etiology. This heterogeneity of responses
is therefore predicted to recapitulate the human ex-
perience, [94] but in the absence of reliable bio-
markers as well as sample size these studies are also
limited by their inability to predict who will benefit.
Another notable agent which has been approved for a
veterinary indication without corresponding approval
in humans is oclacitinib (Apoquel®), a Janus Kinase 2
inhibitor, approved for refractory allergic dermatitis in
dogs. The mechanisms by which oclacitinib work in
dogs is comparable to JAK inhibitors used in humans
for myelodysplastic syndrome and rheumatoid arth-
ritis (with similar side effects) [95].
Although the elements of a canine clinical trial are
comparable to those of a human clinical trial, including
regulatory approval, informed consent, data manage-
ment, and biostatistical design, the time and resources
needed to implement and accrue to canine trials is
viewed as substantially less than with human trials. It is
currently estimated that researchers are conducting hun-
dreds of clinical trials on dogs and cats across the world
(for all indications), and canine clinical trials are gener-
ally viewed as 1 to 2 orders of magnitude less expensive
than human trials (but correspondingly 10–100 fold
more expensive than rodent experiments) [65, 96]. In
addition, as with humans, accrual to trials may be un-
predictable, and results especially given the prevalence
of trials with non-randomized cohorts may be ambigu-
ous. As a result, there is an increasing emphasis to
standardize the veterinary clinical trials infrastructure,
including the National Cancer Institute-supported Com-
parative Oncology Trials Consortium and the recently
developed American Veterinary Medical Association
clinical trials website (https://ebusiness.avma.org/aahsd/
study_search.aspx), akin to www.clinicaltrials.gov. It is
expected that this growing formalization of infrastruc-
ture for companion animal clinical trials will fuel further
support among major funding agencies for companion
animal studies [97].
Advances in canine cancer immunotherapy
Paralleling the rapid adoption of immunotherapy in hu-
man clinical medicine, immunotherapy in canine veter-
inary medicine is gaining increasing utilization for both
approved and investigational indications. For example,
we reported a canine clinical trial in metastatic sarcoma
and melanoma testing a novel immunotherapy combin-
ation including local radiotherapy (RT), intratumoral
CpG oligodeoxynucleotides (immune stimulatory toll-
like receptor 9 agonists), and systemic administration of
indolamine-2,3 dioxygenase (IDO) blockade with 1-
Methyl-Tryptophan (to circumvent immune suppressive
pathways) [98]. The premise of this approach was to as-
sess combination therapies involving conventional treat-
ments which are immunostimulatory with strategies to
inhibit immunosuppressive pathways [99]. This canine
trial was paired with detailed mechanistic studies in mur-
ine models which demonstrated that the triple therapy of
local RT, intratumoral CpG, and systemic IDO not only
reduced intratumoral immune suppression/IDO blockade,
but also induced robust systemic anti-tumor effects and
tumor regression in five dogs with metastatic melanoma
and sarcoma (Fig. 1) [98]. Importantly, a biomarker as
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shown by reduction in circulating and tumor Tregs was ob-
served in responding but not non-responding dogs. The
lack of toxicities associated with the regimen and promising
clinical results is leading to human clinical extrapolation.
An example of cell therapy studies under active inves-
tigation in canine cancers include the recent CD20-
targeting RNA CAR T cells by Panjwani et al. [100].
These authors demonstrated for the first time in dogs
that autologous RNA-transfected CAR T cells could be
generated, expanded, and administered to a dog with re-
lapsed B cell lymphoma. They observed that treatment
was not only well tolerated, but also associated with a
reduction in CD20+ B cells in target lymph nodes at
72 h, providing proof-in-concept that CAR therapies can
be successfully applied in canine patients with the caveat
that more meaningful clinical affects will be contingent
on stable CAR expression as long-term engraftment may
be an issue. Similarly, Mata et al. tested the ability of
genetically modified canine T cells to express a chimeric
human HER2-canine TCR CAR T cell [101]. The authors
demonstrated successful expansion and activation of the
engineered cells which also effectively and selectively
killed HER2-positive target cells using in vitro assays. Al-
though not formally tested in a dog trial as yet, the pre-
clinical work of Mata et al. on CAR T cells illustrates
both the promise and potential barriers of using the
canine model. Unique challenges such as reliance on
better characterized, more widely available human or
mouse-based proteins, cytokines, and transgenes risks
the potential for the consequences of xeno-antibody for-
mation [101, 102]. However, given the risk of severe,
even life-threatening, adverse events with CAR T cell
and other strong immunotherapy regimens, especially
when given systemically, clinical trials of these novel
therapies in dogs should be helpful to answer key ques-
tions about toxicity and efficacy [103].
NK cell immunotherapy approaches are also being
assessed in canine models. At our institution, an ongoing
phase 2 canine clinical trial is evaluating the intratumoral
injection of autologous activated NK cells following pallia-
tive RT for appendicular OSA. Treatment consists of
palliative RT weekly for 1 month, and following RT, dogs
receive two intra-lesional injections of autologous canine
NK cells isolated, expanded, and activated ex vivo, supple-
mented with clinical grade rhIL-2 for in vivo cytokine
support. Another issue in dog immunotherapy studies is
the difficulty in obtaining cost-effective amounts of recom-
binant canine cytokines to be given in vivo for such trials.
Administration of human cytokines will be eventually
neutralized with repeated use. To date, we have accrued
eight patients, and preliminary results have been promising
showing minimal toxicities, supporting the use of the ca-
nine model for the testing of this novel NK approach
(manuscript in preparation). Thus, the canine model is well
suited for adoptive cellular immunotherapy evaluation.
Conclusions
There is a growing body of evidence that the spontan-
eous cancers in dogs represent attractive translational
models that bridge mechanistic studies in mice to the
heterogeneous human situation where clinical trials are
time and resource intensive. Particularly in the burgeon-
ing field of immunotherapy, as a complement to murine
studies and human clinical trials, dogs offer an innova-
tive model for translational research, as they present
many of the same challenges faced in “scaling up” a
therapeutic system dependent on complex interactions
between multiple cell types yet under more controlled
Fig. 1 Efficacy of Radiation + CpG + 1MT in a Canine Clinical Trial. Canines with metastatic melanoma and sarcoma were accrued to a pilot clinical trial
at the UC Davis School of Veterinary Medicine [98]. a. Baseline computed tomography of the thorax demonstrates untreated metastatic lesions in a
dog with buccal melanoma. b. One month after local RT and intra-lesional CPG to the primary tumor combined with systemic indolamine-2,3 dioxygenase
(IDO) inhibition, there is complete regression of some lesions and partial regression of others. Arrows denote index lesions
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settings. They also allow for long-term assessment on
efficacy and toxicities. Canine clinical trials offer unique
access to a rich source of spontaneously occurring,
genetically and immunologically diverse cancers with the
benefits of reduced time, expense, and regulatory hur-
dles of a human trial.
Yet, it is important to recognize that there are disad-
vantages to the canine model, in particular the currently
limited canine-specific/cross-reactive reagents and char-
acterized epitopes available for use. Ultimately, as future
of cancer therapy appears to increasingly point to im-
munotherapy, canine clinical/co-clinical trials represent
an ideal format for the rapid and clinically relevant
translation of novel and high impact immune therapies
and immune combination therapies.
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